表紙
市場調查報告書

Frontier Pharma:第一型糖尿病胰島素基因治療,免疫調節藥物獨佔新標的First-in-Class的開發平台,確證潛在的β細胞再生

Frontier Pharma: Type 1 Diabetes Insulin Gene Therapy and Immuno-modulators Dominate First-in-Class Pipeline with Novel Target Classes Demonstrating Potential Beta-Cell Regeneration

出版商 GlobalData 商品編碼 917386
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
Frontier Pharma:第一型糖尿病胰島素基因治療,免疫調節藥物獨佔新標的First-in-Class的開發平台,確證潛在的β細胞再生 Frontier Pharma: Type 1 Diabetes Insulin Gene Therapy and Immuno-modulators Dominate First-in-Class Pipeline with Novel Target Classes Demonstrating Potential Beta-Cell Regeneration
出版日期: 2019年10月30日內容資訊: 英文 57 Pages
簡介

現在,胰島素是第一型糖尿病患者的主要治療方法,不過,胰島素治療過去90年大幅發展。現在仍有未滿足需求,開發平台開發多樣的治療方法。

本報告提供第一型糖尿病概要與趨勢,市場規模,開發平台趨勢,主要加入企業趨勢等相關資訊。

第1章 目錄

第2章 第一型糖尿病:摘要整理

第3章 簡介

第4章 疾病概要

  • 病因與病理學
  • 第一型糖尿病的分類
  • 第一型糖尿病的持續創新
  • 第一型糖尿病的流行病學
  • 已上市產品概要

第5章 開發中產品創新的評估

  • 概要
  • 各開發階段,各類型分子的開發平台
  • 各分子標的開發平台
  • 計劃比較分佈和各治療標的開發平台
  • 各分子目標種類First-in-Class,非First-in-Class開發平台計劃比較分佈
  • 開發平台的First-in-Class計劃和First-in-Class分子標的比率

第6章 First-in-Class分子標的評估

  • 概要
  • 胰島素
  • 細胞毒性觸發器受體
  • 白細胞介素
  • 卵泡抑素樣
  • 白細胞介素2受體β
  • 巨噬細胞游跑阻止因素
  • 核受體輔助家族5,群組A,成員

第7章 主要加入企業與交易

  • 概要
    • Novo Nordisk與reMYND締結授權契約
    • TetraGenetics和LifeArc締結共同開發契約

第8章 附錄

目錄
Product Code: GDHC498FP

Type 1 diabetes (T1D) is a chronic condition that occurs as a result of the autoimmune destruction of pancreatic beta (B) cells, which are responsible for producing insulin, a hormone needed for body cells to allow for the absorption of glucose in order to produce energy.

Insulin is currently the mainstay treatment for T1D patients, and insulin therapy has significantly evolved over the last 90 years. Still, there is a pressing unmet need within T1D treatment landscape for more diverse, non-insulin disease-modifying pharmacotherapies (immunomodulatory or B-cell preservation). T1D pipeline shows more diverse novel therapies under development. The report assesses first-in-class innovation within the pipeline for T1D.

Scope:

  • T1D pipeline is slightly modest in size, with 243 products at a disclosed stage of active development, however, it is largely novel, diverse and holds considerable potential as opposed to the current homogenous market. What proportion of these products across T1D pipeline are first in class? How does first-in-class innovation vary by development stage and molecular target class?
  • The pipeline mostly encompasses peptides such as novel ultra-rapid formulations of already marketed human insulins and rapid-insulin analogs, biosimilar versions of marketed insulins, and innovative adjunctive therapies that are focused either on immunomodulatory approaches to restore B-cell self-tolerance or on complementing intensive exogenous insulin therapy.
  • Molecular target classes represented in the pipeline include; protein kinase, cytokine signaling, ion channels, SGLT receptors, GABA signaling, glucagon receptor family, antigen, hormone, and nuclear receptor. Which molecular target classes are prominently represented in the overall and first-in-class T1D pipeline?
  • There are 189 companies currently active within the T1D pipeline landscape. Which companies have the most first-in-class assets in development? Which companies are highly active in terms of licensing and co-development deals for first-in-class innovation?

Reasons to buy:

  • Understand the current disease landscape with an in-depth discussion of etiology, pathophysiology, disease classification and staging systems, epidemiology, and marketed therapies for T1D.
  • Analyze the pipelines for T1D, and stratify them by stage of development, molecule type, and molecular target.
  • Assess the therapeutic potential of first-in-class molecular targets. Using proprietary matrix assessments, first-in-class molecular targets for T1D have been assessed and ranked according to clinical potential. Promising first-in-class targets for T1D have been reviewed in greater detail.
  • Analyze company strategies in prior deals through case studies of key deals for T1D first-in-class products, and recognize commercial opportunities by identifying first-in-class pipeline products that have not yet been involved in licensing or co-development deals.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Type 1 Diabetes: Executive Summary

  • 2.1. Current Therapies Leave High Unmet Needs in T1D Treatment Market
  • 2.2. Pipeline Shows Shift Toward Disease-Modifying Approaches
  • 2.3. Innovative First-in-Class Pipeline Products Hold Potential for Beta-Cell Regeneration Therapies

3. Introduction

  • 3.1. Catalyst
  • 3.2. Related Reports
  • 3.3. Upcoming Related Reports

4. Disease Overview

  • 4.1. Etiology and Pathophysiology
    • 4.1.1. Etiology
    • 4.1.2. Pathophysiology
  • 4.2. Classification of T1D
    • 4.2.1. Type 1 Diabetes
  • 4.3. Sustained Innovation in T1D
  • 4.4. Epidemiology for T1D
  • 4.5. Overview for Marketed Products

5. Assessment of Pipeline Product Innovation

  • 5.1. Overview
  • 5.2. Pipeline by Stage of Development and Molecule Type
  • 5.3. Pipeline by Molecular Target
  • 5.4. Comparative Distribution of Programs Between the T1D Market and Pipeline by Therapeutic Target Family
  • 5.5. Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
    • 5.5.1. Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs
  • 5.6. Ratio of First-in-Class Programs to First-in-Class Molecular Target Within the Pipeline

6. First-in-Class Molecular Target Evaluation

  • 6.1. Overview
  • 6.2. Pipeline Programs Targeting Insulin
  • 6.3. Pipeline Programs Targeting Natural Cytotoxicity Triggering Receptor
  • 6.4. Pipeline Programs Targeting Interleukin
  • 6.5. Pipeline Programs Targeting Follistatin-like
  • 6.6. Pipeline Programs Targeting Interleukin
  • 6.7. Pipeline Programs Targeting Interleukin 2 Receptor Beta
  • 6.8. Pipeline Programs Targeting Macrophage Migration Inhibitory Factor
  • 6.9. Pipeline Programs Targeting Nuclear Receptor Subfamily 5, Group A, Member

7. Key Players and Deals

  • 7.1. Overview
    • 7.1.1. Novo Nordisk Entered into a Licensing Agreement with reMYND
    • 7.1.2. TetraGenetics Entered into a Co-development Agreement with LifeArc

8. Appendix

  • 8.1. Bibliography
  • 8.2. Abbreviations
  • 8.3. Methodology
    • 8.3.1. Market Analysis
    • 8.3.2. Overall Pipeline Analysis
    • 8.3.3. First-in-Class Pipeline Analysis
    • 8.3.4. First-in-Class Matrix Assessment
    • 8.3.5. First-in-Class Molecular Target Evaluation
    • 8.3.6. Key Players and Deals
  • 8.4. About the Authors
    • 8.4.1. Analyst
    • 8.4.2. Therapy Area Director
    • 8.4.3. Global Director of Therapy Analysis and Epidemiology
    • 8.4.4. Global Head and EVP of Healthcare Operations and Strategy
  • 8.5. About GlobalData
  • 8.6. Contact Us
  • 8.7. Disclaimer

List of Tables

  • Table 1: Classification of T1D
  • Table 2: T1D Total Prevalent Cases, millions (N), 2016-2026

List of Figures

  • Figure 1: Etiology of T1D
  • Figure 2: Types and Stages of Diabetes
  • Figure 3: T1D, Global Market by Molecular Target and Molecule Type, 2019
  • Figure 4: T1D, Global Pipeline by Stage of Development and Molecule Type, 2019
  • Figure 5: T1D Pipeline by Molecular Target and Stage of Development, 2019
  • Figure 6: T1D, Global Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019
  • Figure 7: T1D, Global Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019
  • Figure 8: T1D, Global Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019
  • Figure 9: T1D, Global Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019
Back to Top